[BIIB] Biogen: Q3 2026 Earnings Test Whether Growth Products Can Outrun MS Erosion

Biogen is a biopharmaceutical company focused on neuroscience, rare disease and specialized immunology, with marketed drugs for multiple sclerosis (MS), spinal muscular atrophy (SMA), Friedreich's ataxia (FA) and amyotrophic lateral sclerosis (ALS), and it co-commercializes the Alzheimer's drug LEQEMBI with Eisai[1]. Biogen's Q3 2026 earnings call is scheduled for 2026-10-28 and will cover the Third quarter 2026 (three months ended September 30, 2026)[2]. In the latest disclosed quarter, the second quarter of 2026, total revenue rose 3% year over year to $2.736 billion, and the Growth Portfolio generated $1.06 billion, up 24%, overtaking the $767 million legacy MS portfolio for the first time; GAAP diluted EPS was $0.66 and non-GAAP diluted EPS was $3.60, including $164 million of acquired in-process R&D expense, and net debt stood at about $6.8 billion on June 30[3]. On July 29 the company changed its 2026 revenue guidance to mid-single-digit percentage growth and set full-year non-GAAP diluted EPS guidance at $12.00 to $13.00, which already includes about $0.85 of dilution from the Apellis acquisition[3]; separately, on July 1 it said third-quarter acquired IPR&D, upfront and milestone expense would be roughly $290 million to $320 million, an EPS impact of about $1.75 to $1.95[4]. Analyst consensus compiled by Drillr puts third-quarter revenue at $2.64 billion (21 analysts, range $2.44 billion to $2.72 billion) and EPS at $1.99 (18 analysts, range $1.62 to $2.53, basis not specified)[5].

Three things matter most in this report. The first is whether the high-dose SPINRAZA gain sticks: U.S. SPINRAZA revenue rose 36.8% to $204.3 million in the second quarter, and the company's quarterly report attributed that increase to demand and channel stocking for the high-dose regimen[6], so whether U.S. growth stays above 15% in the third quarter will show whether this is real demand or one-time stocking. The second is the first full quarter of Apellis inside Biogen: SYFOVRE generated $162 million of full-quarter revenue in the second quarter, up 8%[3], with commercial injections up 13%[7], while the deal lifted net debt from about $1.5 billion on March 31 to about $6.8 billion[8][3]; the third quarter will be the first to carry a full quarter of both product revenue and financing cost, a direct test of the company's roughly $0.85 full-year dilution estimate. The third is the pace of legacy MS decline: second-quarter U.S. TYSABRI revenue of $270.5 million was essentially flat against $272.2 million a year earlier[3], but the quarterly report shows U.S. demand fell because of competition and was offset by price[6], and once the price effect fades, the gap the Growth Portfolio has to fill will widen.

Company Background and Business Structure

Biogen reports as a single operating segment but discloses revenue by product line, and MS is still the largest line. MS product revenue fell 7.1% to $4,038.9 million in 2025 and includes the infused antibody TYSABRI, the oral drugs VUMERITY and TECFIDERA, and the interferons AVONEX and PLEGRIDY[1]. TECFIDERA fell 29.7% to $679.7 million because of multiple generic entrants, and TYSABRI fell 2.9% to $1,665.4 million, partly because a TYSABRI biosimilar entered Europe[1].

Rare disease and biosimilars are the other two owned product lines; the first is growing and the second is shrinking. The rare disease line includes the SMA drug SPINRAZA, the FA drug SKYCLARYS and the ALS drug QALSODY, and it grew 8.4% to $2,154.2 million in 2025, while biosimilars revenue fell 8.1% to $729.1 million, mainly from BENEPALI, IMRALDI and FLIXABI sold in Europe[1]. The postpartum depression drug ZURZUVAE is commercialized with Supernus[1] and sits in other products.

The Apellis acquisition, completed on May 14, 2026, added a specialized immunology product line[3]. Apellis shareholders received $41.00 in cash per share, about $5.3 billion in total, plus a contingent value right worth up to $4.00 per share tied to annual global SYFOVRE sales thresholds[6]. SYFOVRE treats geographic atrophy (GA, an advanced form of dry macular degeneration), and EMPAVELI is growing quickly in rare kidney diseases such as C3G[7].

Beyond product revenue, Biogen has two important collaboration revenue streams. It receives a tiered royalty from Genentech on U.S. OCREVUS sales, starting at 13.5% and rising to 24.0% when annual net sales exceed $900 million, and the rate is cut in half once the first FDA-approved OCREVUS biosimilar enters the U.S.[1]; second-quarter 2026 revenue from anti-CD20 programs totaled $513.5 million, including $381.4 million of OCREVUS royalties and $125.7 million of U.S. pre-tax profit share on RITUXAN, GAZYVA and LUNSUMIO[3]. Eisai books LEQEMBI sales, and Biogen records its 50% share of LEQEMBI net revenue less cost of sales as Alzheimer's collaboration revenue[1]; contract manufacturing, royalty and other revenue was $732.9 million in 2025[1].

Biogen's U.S. channel is concentrated, and its manufacturing rests on two owned sites. In the U.S. it sells mainly through wholesalers, specialty distributors and specialty pharmacies, and in 2025 two wholesalers together accounted for about 43.9% of gross product revenue[1]. The company manufactures in Research Triangle Park, North Carolina, and in Solothurn, Switzerland, where the plant is approved to make LEQEMBI and TYSABRI[1].

Financial History and Current Position

In 2025 Biogen's revenue grew slightly while operating cash flow fell noticeably. According to the 2025 10-K, total revenue rose 2.2% to $9,890.6 million, of which product revenue fell 1.3% to $7,119.4 million[1]. Cash, cash equivalents and marketable securities were about $4.2 billion at year end, up from about $2.4 billion a year earlier, and operating cash flow was about $2.2 billion versus about $2.9 billion in 2024, with part of the gap coming from roughly $864.0 million of tax payments driven by timing[1].

In the first quarter of 2026, revenue growth was close to the prior year's pace and the balance sheet was still comfortable before the acquisition. First-quarter total revenue was about $2.5 billion, up 2%, GAAP diluted EPS was $2.15, up 31%, and non-GAAP diluted EPS was $3.57, up 18%; operating cash flow was about $646 million and free cash flow about $594 million[8]. On March 31 the company held about $4.7 billion of cash against about $6.3 billion of total debt, for net debt of about $1.5 billion, and its full-year revenue guidance at that time still called for a mid-single-digit percentage decline[8].

Second-quarter 2026 revenue outpaced the first quarter, but deal-related charges held down profit. Total revenue was $2,736.0 million (versus $2,645.5 million a year earlier), product revenue was $1,916.4 million, GAAP diluted EPS was $0.66 and non-GAAP diluted EPS was $3.60[3]. Non-GAAP cost of sales was 22% of revenue (21% a year earlier), non-GAAP R&D was $489.5 million and non-GAAP SG&A was $679.6 million, non-GAAP other expense was about $60 million, mainly net interest expense that includes acquisition financing costs, and the non-GAAP effective tax rate was 17.2%[3].

The acquisition moved Biogen from near net cash to about $6.8 billion of net debt. Second-quarter operating cash flow was about $449 million, capital expenditures about $41 million and free cash flow about $408 million; on June 30 the company had about $1.3 billion of cash, about $8.1 billion of total debt and about $6.8 billion of net debt[3]. First-half operating cash flow was $1,094.4 million, purchases of property, plant and equipment were $92.1 million, and the Apellis acquisition, net of cash acquired, cost $5,065.1 million; Biogen bought back no stock in the first half and had about $2.1 billion left under its repurchase authorization[6].

Operating Model

Biogen's revenue is the sum of four parts, and each has different drivers. Total revenue equals product revenue plus anti-CD20 program revenue, Alzheimer's collaboration revenue and contract manufacturing and other revenue; product revenue is roughly patients on therapy times doses times net price after discounts and rebates, adjusted for channel inventory and the timing of international orders, and in the second quarter it comprised MS at $963.3 million, rare disease at $601.7 million, specialized immunology at $127.8 million (post-close), biosimilars at about $153 million and other at about $71 million, for a total of $1,916.4 million[3]. Inventory and shipment timing can swing results for a quarter or two: second-quarter VUMERITY revenue fell 7.4% on inventory dynamics, and ex-U.S. SPINRAZA revenue fell 18.8% on shipment timing in certain markets[6]. Anti-CD20 revenue is roughly U.S. OCREVUS sales times the tiered royalty rate, plus U.S. pre-tax profit share on RITUXAN, GAZYVA and LUNSUMIO[3]; Alzheimer's collaboration revenue is roughly 50% of LEQEMBI net revenue less cost of sales[1].

Operating profit is revenue less four types of expense, and acquired IPR&D is the most volatile of them. Non-GAAP operating profit is roughly total revenue less non-GAAP cost of sales (22% of revenue in the second quarter), non-GAAP R&D, non-GAAP SG&A and acquired IPR&D, which was $164 million in the second quarter against only $47 million a year earlier[3]; the same charge was about $34 million in the first quarter[9] and is guided at about $290 million to $320 million for the third[4], and because it comes from deals and milestones, it lowers profit directly and one quarter at a time. GAAP profit also absorbs amortization of acquired intangibles ($168.2 million in the second quarter)[3] and amortization of inventory fair value step-ups: the Apellis inventory step-up of about $567.5 million will be fully amortized by the end of 2029, and about $69.7 million was already charged to cost of sales in the second quarter[6], one of the main reasons GAAP cost of sales was 28% of revenue while the non-GAAP figure was 22%[3]. Moving from operating profit to non-GAAP EPS subtracts about $60 million of non-GAAP other expense and a 17.2% tax rate, spread over about 149 million shares[3].

Operating cash flow follows net income but moves with tax and working-capital timing, and its main use now is repaying acquisition debt. After patients are treated, wholesalers and specialty pharmacies pay on credit terms and Genentech settles anti-CD20 amounts; operating cash flow is roughly net income plus amortization and stock compensation, adjusted for the timing of receivables, inventory and taxes, and in 2025 about $864.0 million of tax timing pulled down full-year cash flow[1]. Apellis's cash consideration was funded with cash and marketable securities on hand, a $2.0 billion term loan and a $400 million revolver draw[6]; $200 million of the term loan had been repaid by the second quarter, and management plans to repay it in full by the end of 2027[7], while the company expects run-rate deal synergies of at least $250 million exiting 2027[3].

Industry and Competitive Position

In MS, Biogen remains an established supplier, but its core drugs have entered the generic and biosimilar cycle. TECFIDERA faces multiple generics, a TYSABRI biosimilar was approved in the U.S. and the E.U. in 2023, and interferon patients are moving to higher-efficacy therapies[1]. On the second-quarter call management said TYSABRI demand had held up against biosimilar competition in the U.S. and Europe[7], but that view is not yet backed by patient-level disclosure.

In rare disease and ophthalmology, Biogen's products must compete with oral drugs and also expand underdiagnosed patient pools. Management said high-dose SPINRAZA starts and fills in the first 13 weeks of the U.S. launch exceeded the original standard-dose launch, with volume coming from existing patients switching dose, new patients (including infants who had not been dosed in years) and patients returning from the competing oral SMA therapy[7]; on the first-quarter call, management said ex-U.S. markets were seeing similar traction[10]. SYFOVRE leads the geographic atrophy market, but management said only about 20% of GA patients are diagnosed and only about 50% of retina specialists treat the condition[7], and it described the GA market as sensitive to promotion[10].

In Alzheimer's disease, Biogen competes by changing how the drug is given, but most of the material available for comparison comes from the company itself. LEQEMBI IQLIK is the first anti-amyloid treatment offering at-home administration and is FDA-approved as an initiation dose[3]; the company has also disclosed that most patients continued treatment into the maintenance phase at 18 months[8]. Biogen does not disclose product-level patient counts, prices or days of inventory, the SYFOVRE injection and high-dose SPINRAZA conversion figures come from a call summary rather than a verbatim transcript, and competitors' same-period data are outside this comparison, so the assessment of competitive position rests mainly on Biogen's own revenue and management commentary.

Core Debates

With TECFIDERA largely displaced by generics, how long can TYSABRI hold off its biosimilar?

The pace of legacy MS decline determines how large a gap the Growth Portfolio must fill first. MS product revenue of $4,038.9 million was about 40.8% of 2025 total revenue of $9,890.6 million[1]; the legacy MS portfolio (AVONEX, PLEGRIDY, TECFIDERA and TYSABRI) generated $767 million in the second quarter, down about 14% from $894.9 million a year earlier[3]. Even so, the company raised its full-year revenue guidance from a mid-single-digit decline to mid-single-digit growth, citing resilient TYSABRI demand as one reason[7].

The evidence shows TECFIDERA has already been heavily displaced, while TYSABRI is holding revenue mainly through U.S. pricing. Second-quarter global TYSABRI revenue was $450.8 million, down 0.8%, and U.S. revenue was $270.5 million, down 0.6%[3]; the quarterly report attributed the decline to lower U.S. demand from competition, partly offset by a favorable U.S. pricing change and currency[6]. TECFIDERA revenue outside the U.S. fell from $146.4 million to $58.5 million, a drop of about 60%, and full-year 2025 global TECFIDERA revenue was $679.7 million[3][1]. VUMERITY revenue fell 7.4% to $196.5 million in the second quarter, mainly on channel inventory[6], but still grew 7% in the first half[3]; in both its annual report and its second-quarter report, the company said TYSABRI sales will continue to be hurt by the biosimilar[1][6].

The financial transmission in this debate is direct. Accelerating TECFIDERA generic competition in Europe, TYSABRI biosimilar expansion in the U.S. and Europe, and interferon patients moving to higher-efficacy drugs all reduce legacy MS volume and net price, which lowers MS product revenue and shrinks the share of revenue coming from older, higher-margin products[1]; the Growth Portfolio has to fill that gap before total revenue can reach the raised mid-single-digit growth guidance[3]. An alternative explanation is that TYSABRI's resilience comes mainly from U.S. price increases, and if the biosimilar gains U.S. prescriptions, demand losses would show up all at once after the price effect fades, making the decline steeper than the second-quarter numbers suggest.

What remains unresolved is how long the balance between U.S. demand loss and pricing can hold. In the third quarter, the key checks are whether the legacy MS decline stays within about 14%, whether U.S. TYSABRI revenue stays within -5% year over year and how management splits price from demand, and whether VUMERITY returns to year-over-year growth once inventory normalizes[3][6]. A U.S. TYSABRI decline of more than 5% would show the biosimilar starting to erode U.S. demand; a legacy MS decline held within 15% with flat TYSABRI revenue would support the slow-decline view.

SPINRAZA's high-dose regimen lifted U.S. sales; how much of the second-quarter gain will persist into the third quarter?

SPINRAZA is one of Biogen's largest products and the main lever for reversing the decline in its rare disease business. In its 2025 annual report the company said it anticipated relatively flat global SPINRAZA revenue in 2026[1], and the high-dose regimen was then approved in Japan, the E.U. and the U.S.[8]. U.S. SPINRAZA revenue rose 36.8% in the second quarter, but the quarterly report made clear that this included launch-quarter stocking for the high dose[6], so whether that growth continues bears directly on rare disease revenue and the Growth Portfolio.

The data show U.S. demand improving, but ex-U.S. shipment timing and stocking make a single quarter hard to read. Second-quarter global SPINRAZA revenue was $401.9 million, up 2%, U.S. revenue was $204.3 million (versus $149.3 million a year earlier), and revenue outside the U.S. was $197.6 million, down 18.8%, mainly because of shipment timing in certain international markets[6]. On the first-quarter call management said about 20% of the patient base had submitted high-dose start forms[10]; in the second quarter the company said dose conversion was ahead of its expectations in all launched geographies[3]. In the same product line, SKYCLARYS revenue rose 28.9% to $167.9 million, with ex-U.S. revenue of $85.6 million versus $52.3 million a year earlier, a gain of about 63.7%[6][3]; full-year 2025 SKYCLARYS revenue was $520.5 million, up 36.1%[1], and second-quarter rare disease revenue totaled $601.7 million, up about 10.8%[3].

The high-dose regimen feeds into revenue with a clear time lag. Patients on therapy switching dose, some oral-therapy patients returning and new patient starts cause loading doses and U.S. channel stocking to be recognized up front in the second quarter; from the third quarter onward, revenue depends more on maintenance doses and new patients, with the timing of ex-U.S. government orders layered on top[6][7]. An alternative explanation is that the U.S. gain came mainly from channel stocking and loading doses, that annual doses per patient do not rise once patients reach maintenance, and that U.S. growth will drop sharply in the third quarter, leaving the full year only relatively flat as the annual report anticipated[1]; because the company does not split demand from stocking, neither explanation can yet be ruled out.

The third-quarter numbers will be the first test that can separate demand from stocking. The checks are whether U.S. SPINRAZA growth stays above 15% and whether management mentions inventory drawdown, whether global SPINRAZA stops declining and how large the ex-U.S. timing effect is, and whether SKYCLARYS growth stays above 20%[6]. If U.S. SPINRAZA growth falls below 15%, the second quarter was mostly stocking; if U.S. growth stays above 15% and global revenue turns positive year over year, that supports real demand from the high-dose regimen.

Can SYFOVRE keep growing in its first full quarter inside Biogen and offset the financing cost of the $5.3 billion Apellis deal?

The Apellis acquisition pushed Biogen from low leverage to meaningfully higher leverage, and the third quarter is the first to show the deal's full revenue and cost. Cash consideration was about $5.3 billion[6], lifting quarter-end net debt from about $1.5 billion in the first quarter to about $6.8 billion[8][3]; the company expects the deal to dilute 2026 non-GAAP diluted EPS by about $0.85, largely through lower interest income and higher interest expense, and said it will become accretive in 2027[3].

Second-quarter data show both products growing, but revenue growing more slowly than volume. On a full-quarter basis SYFOVRE revenue was $162 million, up 8% both year over year and sequentially, with $97.4 million recognized by Biogen after the close; EMPAVELI revenue was $46 million, up 123% year over year, with $30.4 million recognized after the close[3], and up 12% sequentially[7]. Management said SYFOVRE commercial injections rose 13% year over year, that June 2026 was its best single month ever, and that reducing early drop-off should further improve growth[7]; on the first-quarter call management also expressed optimism about a prefilled syringe[10]. On the cost side, second-quarter non-GAAP other expense was about $60 million[3], management had said in the first quarter that the deal would affect the 2026 non-GAAP other income and expense line by $120 million to $130 million[10], and $200 million of the $2.0 billion term loan had been repaid by the second quarter[7][6].

The deal's financial transmission works on both revenue and expense. The cash consideration was paid with cash on hand, a $2.0 billion term loan and a temporary revolver draw, which lowers interest income, raises interest expense and pushes up non-GAAP other expense[6]; at the same time SYFOVRE and EMPAVELI revenue, along with the related selling and R&D costs, are consolidated, and the company expects run-rate synergies of at least $250 million exiting 2027, using product growth and synergies to offset financing costs[3]. Under GAAP, about $567.5 million of inventory step-up will keep flowing through cost of sales until the end of 2029[6]. An alternative explanation is that competition in geographic atrophy is still shifting and that injection growth well above revenue growth means net price per injection is falling; if third-quarter SYFOVRE revenue is flat sequentially, a full quarter of interest and inventory step-up amortization could push 2026 dilution above $0.85.

What remains unresolved is whether product growth can outrun a full quarter of financing cost. In the third quarter, the checks are whether SYFOVRE revenue exceeds $162 million and injection growth holds near 13%, whether non-GAAP other expense lands between $60 million and $90 million, whether the company keeps its roughly $0.85 full-year dilution estimate, and whether term-loan repayment continues[3][7]. A sequential decline in SYFOVRE revenue or injection growth below 8% would weaken the revenue case for the deal; sequential SYFOVRE growth with the dilution estimate intact would support accretion in 2027.

With the at-home IQLIK injection launched, can LEQEMBI break the infusion bottleneck and accelerate in the U.S.?

LEQEMBI is Biogen's main Alzheimer's product, but under the 50/50 split its contribution to Biogen's profit is still negative. Biogen's second-quarter Alzheimer's collaboration revenue was $63.7 million (versus $54.9 million a year earlier) and $123.2 million for the first half[3]; over the same periods, Biogen's share of LEQEMBI sales and marketing expense was $77.6 million (versus $85.7 million) and $162.3 million[6]. IQLIK is the first anti-amyloid treatment offering at-home administration and is FDA-approved as an initiation dose[3], and management said it would be commercially available by the end of August 2026, making the third quarter its first launch quarter[7].

The data show U.S. LEQEMBI sales growing sequentially, while IQLIK demand so far shows up only as prescriptions waiting in a queue. Second-quarter global LEQEMBI in-market sales were $184 million, up 15%, and U.S. in-market sales were $97 million[3], up from $86 million in the first quarter, when global in-market sales were $168 million, up 74%[8]. Management said several hundred IQLIK prescriptions were already waiting for launch, that market research shows a large share of patients stop treatment specifically to avoid IV infusion, and that medical exception approval rates for maintenance dosing have been very high[7].

IQLIK raises both revenue and expense on Biogen's income statement. IQLIK is approved for initiation and maintenance and can be injected at home; by removing IV infusion it could expand the treatable population and improve persistence, lifting the in-market sales Eisai books and therefore Biogen's 50% share of collaboration revenue[1]; at the same time launch promotion costs rise, and Biogen bears 50% of them within selling expense[6]. An alternative explanation is that 2027 Part D contracting is still pending[7], so the at-home form can rely only on medical exceptions for reimbursement in 2026, and with only about one month on the market in the third quarter, the incremental revenue will be limited while promotion spending rises first.

What remains unresolved is whether the at-home form can deliver enough added volume before its costs rise. In the third quarter, the checks are whether U.S. LEQEMBI in-market sales exceed $97 million, whether Biogen's collaboration revenue exceeds $63.7 million and its shared selling expense exceeds $100 million, and how the first IQLIK prescriptions convert and 2027 Part D contracting progresses[3][6][7]. A sequential decline in U.S. in-market sales would show that IQLIK did not expand the treated population; sequential U.S. growth above 13% would support acceleration from the at-home form.

Risks and Falsifiers

Acquired IPR&D, upfront and milestone charges can swing EPS sharply, and a large charge has already been flagged for the third quarter. On July 1 the company said third-quarter charges of this kind would be about $290 million to $320 million, tied to transactions that have not yet closed and potential milestones, with an impact on GAAP and non-GAAP EPS of about $1.75 to $1.95[4]; the $12.00 to $13.00 full-year non-GAAP EPS guidance already reflects completed and expected transactions and milestones[3]. If the actual third-quarter charge lands within $290 million to $320 million and the company adds no unannounced charges of the same type, this risk stays within the range the company gave.

OCREVUS royalties depend on sales by Roche's Genentech and face a one-time rate cut. Once the first FDA-approved OCREVUS biosimilar enters the U.S., Biogen's royalty rate will be cut in half[1]; anti-CD20 program revenue was $1,860.6 million in 2025, about 18.8% of total revenue[1], and second-quarter 2026 OCREVUS royalties were $381.4 million (versus $353.8 million a year earlier)[3]. If no OCREVUS biosimilar has been approved in the U.S. by the third quarter and anti-CD20 revenue keeps growing year over year, this risk has not materialized.

Wider U.S. prescribing of the TYSABRI biosimilar could make demand losses outweigh the price effect. Global TYSABRI revenue was $1,665.4 million in 2025[1] and U.S. revenue was $270.5 million in the second quarter[3], so each 10% decline in U.S. revenue would cut quarterly revenue by about $27 million. If third-quarter U.S. TYSABRI revenue changes by no more than 5% in either direction year over year, the current slow-decline view is not falsified.

The second-quarter U.S. SPINRAZA gain could prove to be mostly one-time stocking, with inventory drawdown in the third quarter returning the full year to decline. U.S. SPINRAZA revenue rose $55.0 million year over year in the second quarter[6]; if the full year reverts to the first half's pace of about -5.0%, revenue would be about $77 million below the 2025 level of $1,546.8 million[1][3]. If third-quarter U.S. SPINRAZA growth exceeds 15%, this risk is weakened.

Slower SYFOVRE growth, combined with a full quarter of financing cost and inventory step-up amortization, could make the deal more dilutive than the company expects. Cash consideration was about $5.3 billion, a contingent value right of up to $4.00 per share is tied to annual global SYFOVRE sales thresholds, and about $567.5 million of inventory step-up will run through GAAP cost of sales until the end of 2029[6]; the company estimates 2026 non-GAAP EPS dilution of about $0.85[3]. If third-quarter SYFOVRE revenue exceeds $162 million and the company keeps its $0.85 dilution estimate, this risk has not materialized.

Limited IQLIK reimbursement and a slower-than-hoped ramp, with Biogen paying launch promotion costs up front, could keep LEQEMBI's profit contribution negative. Biogen's second-quarter collaboration revenue was $63.7 million[3], below its $77.6 million share of LEQEMBI sales and marketing expense[6], and management acknowledged that 2027 Part D contracting is still pending[7]. If third-quarter collaboration revenue grows sequentially and exceeds the shared selling expense, this risk is falsified.

What to Watch Next

• Legacy MS erosion: the legacy MS portfolio generated $767 million in the second quarter, down about 14%, U.S. TYSABRI revenue was $270.5 million (-0.6%) and VUMERITY was $196.5 million (-7.4%). A U.S. TYSABRI decline of more than 5% would weaken the case; a legacy MS decline within 15% with flat TYSABRI would strengthen it.
• High-dose SPINRAZA: second-quarter U.S. revenue was $204.3 million (+36.8%, including stocking), global revenue $401.9 million (+2%) and SKYCLARYS $167.9 million (+28.9%). U.S. growth below 15% would point to stocking; growth above 15% with global revenue turning positive would strengthen the case.
• Apellis consolidation and financing: SYFOVRE revenue was $162 million (+8%) with injections up 13%, non-GAAP other expense about $60 million and $200 million of the term loan repaid. A sequential revenue decline or injection growth below 8% would weaken the case; sequential growth with the $0.85 dilution estimate intact would strengthen it.
• LEQEMBI IQLIK: U.S. in-market sales were $97 million, collaboration revenue $63.7 million and shared selling expense $77.6 million. A sequential decline in U.S. in-market sales would weaken the case; sequential growth above 13% would strengthen it.
• One-time charges: third-quarter acquired IPR&D is guided at about $290 million to $320 million, an EPS impact of about $1.75 to $1.95. A charge within the range with no new unannounced items leaves the basis of full-year guidance unchanged.

Conclusion

Biogen's results are shaped by a shrinking legacy MS line and an expanding set of growth products. In the second quarter of 2026 the Growth Portfolio generated $1.06 billion, up 24%, overtaking the $767 million legacy MS portfolio for the first time, and total revenue rose 3% to $2.736 billion[3]; after the Apellis acquisition, however, net debt rose from about $1.5 billion at the end of March to about $6.8 billion[8][3], and the $12.00 to $13.00 full-year non-GAAP EPS guidance already includes about $0.85 of deal dilution[3]. The central unresolved relationship is whether the gains from high-dose SPINRAZA, SYFOVRE and LEQEMBI IQLIK, after stocking and promotion costs, can keep outrunning the erosion of TYSABRI and TECFIDERA and a full quarter of financing costs.

Since the July 29, 2026 results, the third-party material available consists only of brokers' adjustments to their stock views and one broker's quarterly EPS figure, and none of it offers an independent interpretation of the core debates above, so no outside views are used here and this material is not treated as a shared market view. The current assessment can rest only on company disclosures and management commentary, and management's statements on TYSABRI demand resilience, high-dose SPINRAZA conversion and queued IQLIK prescriptions[7] are the company's own account, which third-quarter and later results will need to verify.

The combination that would materially strengthen the current understanding is third-quarter U.S. SPINRAZA growth above 15% with global revenue turning positive year over year, SYFOVRE revenue above $162 million with the company keeping its roughly $0.85 dilution estimate, a U.S. TYSABRI decline within 5%, and continued sequential growth in U.S. LEQEMBI in-market sales with collaboration revenue moving closer to the shared selling expense. Conversely, if U.S. SPINRAZA growth falls below 15% and SYFOVRE revenue declines sequentially, while the U.S. TYSABRI decline exceeds 5% or acquired IPR&D exceeds the guided range, the view that the Growth Portfolio can fill the legacy gap would be clearly weakened.

Sources

[1] BIIB FY2025 10-K filed 2026-02-06 · 2026-02-06 · 10-K · https://www.sec.gov/Archives/edgar/data/875045/000087504526000013/biib-20251231.htm

[2] BIIB earnings calendar updated 2026-10-23 · 2026-10-23 · Drillr earnings calendar

[3] BIIB Q2 2026 8-K filed 2026-07-29 · 2026-07-29 · 8-K · https://www.sec.gov/Archives/edgar/data/875045/000087504526000073/exhibit991-q22026pressrele.htm

[4] BIIB 8-K filed 2026-07-01 (Q2/Q3 2026 acquired IPR&D) · 2026-07-01 · 8-K · https://www.sec.gov/Archives/edgar/data/875045/000087504526000068/biib-20260701.htm

[5] Drillr analyst estimates BIIB Q3 2026 retrieved 2026-10-23 · 2026-10-23 · Drillr analyst estimates · https://gateway.drillr.ai/mcp/private

[6] BIIB Q2 2026 10-Q filed 2026-07-29 · 2026-07-29 · 10-Q · https://www.sec.gov/Archives/edgar/data/875045/000087504526000075/biib-20260630.htm

[7] BIIB Q2 2026 earnings call 2026-07-29 · 2026-07-29 · earnings-call · https://gateway.drillr.ai/mcp/private

[8] BIIB Q1 2026 8-K filed 2026-04-29 · 2026-04-29 · 8-K · https://www.sec.gov/Archives/edgar/data/875045/000087504526000042/exhibit991-q12026pressrele.htm

[9] BIIB 8-K filed 2026-04-06 (Q1 2026 acquired IPR&D) · 2026-04-06 · 8-K · https://www.sec.gov/Archives/edgar/data/875045/000087504526000039/biib-20260406.htm

[10] BIIB Q1 2026 earnings call 2026-04-29 · 2026-04-29 · earnings-call · https://gateway.drillr.ai/mcp/private